CURE Pharmaceutical Holding Corp. (CURR)
| Market Cap | 11.42M |
| Revenue (ttm) | 5.63M |
| Net Income (ttm) | -22.72M |
| Shares Out | 71.38M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,496 |
| Open | 0.156 |
| Previous Close | 0.155 |
| Day's Range | 0.156 - 0.197 |
| 52-Week Range | 0.14 - 0.54 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CURR
CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Vir... [Read more]
News
CURE Pharmaceutical Reports Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases an...
New Marketing Programs Showing Encouraging Early Results SHERMAN OAKS, CA / ACCESSWIRE / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad...
Avenir Wellness Solutions to Present at Investor Summit Group's Q4 Conference
Sherman Oaks, California--(Newsfile Corp. - November 10, 2022) - Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) today announced that CEO Nancy Duitch will be att...
Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV
Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern)Oxnard, California--(Newsfile Corp. - October 24, 2022) - Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad ...
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member o...
Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of...
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder...
CURE Pharmaceutical Announces the Appointment of New Board Member
Gerald Bagg brings deep understanding of CPG to CURE Gerald Bagg brings deep understanding of CPG to CURE
CURE Pharmaceutical Announces Teleconference With Investors
Updates on Recent Transaction and Business will be Provided Updates on Recent Transaction and Business will be Provided
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Propri...
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children's Hospital Medical Center (CCHMC) U...
OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, ...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thi...
COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's...
Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leadi...
Northern Response International To Distribute Seratopical Revolution® Masstige Line Northern Response International To Distribute Seratopical Revolution® Masstige Line
CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue™ Technology
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and he...
CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal
Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC:CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year increa...
CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million r...
Seratopical Revolution Skincare Line by The Sera Labs Inc., a CURE Pharmaceutical Company, will be Available for Purc...
LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that all six facial products of the Seratopical Revolution skincare line will be a...
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health...
Federally Compliant Medical Cannabis In The US? One Company Is Doing It
CURE Pharmaceutical (OTC:CURR) has signed an agreement with Biopharmaceutical Research Company (BRC) to produce federally compliant medical cannabis, CBD and THC products. BRC will provide the cannabino...
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Vet...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership ag...
CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with th...
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Ps...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an oper...
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
LOS ANGELES--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has ...
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m.
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE's Chief Exe...
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for th...
CURE Pharmaceutical Augments Its Existing U.S. DEA License in Order to Initiate Development of Its Psychedelics-Based...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it h...